{
  "id": "non-small-cell-lung-cancer",
  "title": "Non-Small-Cell Lung Cancer",
  "lang": "en",
  "source_lang": "en",
  "summary": "Non-small-cell lung cancer comprises several lung malignancies whose diagnosis and treatment depend on histology, anatomical stage, and molecular characteristics.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "NSCLC",
    "Non-small cell lung carcinoma",
    "Non-small-cell carcinoma of the lung"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/non-small-cell-lung-cancer/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/non-small-cell-lung-cancer/",
      "json": "https://aiwiki.page/zh/non-small-cell-lung-cancer.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Non-small-cell lung cancer (NSCLC) is a group of malignant epithelial tumors arising in the lung, principally adenocarcinoma and squamous cell carcinoma. It accounts for approximately 80–85% of lung cancers. The term originally distinguished these tumors from small-cell lung cancer because of differences in microscopic appearance, clinical behavior, and treatment. NSCLC is not a single biological disease: tumors with similar appearances can have different genetic drivers, patterns of spread, and responses to treatment.\n\nNSCLC is a major cause of cancer-related illness and death worldwide. Tobacco smoking is its largest preventable cause, but the disease also occurs in people who have never smoked. Diagnosis combines tissue examination with imaging and, increasingly, molecular testing. Treatment ranges from surgery or focused radiation for localized disease to combinations of chemotherapy, immunotherapy, and molecularly targeted drugs for more extensive disease. Anatomical stage remains central to prognosis, while tumor biology increasingly determines which treatments are effective."
    },
    {
      "heading": "Histological classification and pathological features",
      "text": "NSCLC is a practical clinical grouping within pulmonary carcinoma, rather than a single diagnosis defined by one cellular origin. Its principal categories are lung adenocarcinoma and lung squamous cell carcinoma. Less common forms include adenosquamous carcinoma, large-cell carcinoma, and sarcomatoid carcinomas. Pulmonary neuroendocrine tumors require separate classification: small-cell carcinoma is excluded from NSCLC, and large-cell neuroendocrine carcinoma has distinct biological and therapeutic considerations despite its name.\n\nAdenocarcinoma shows glandular differentiation, mucin production, or characteristic immunohistochemical findings. It commonly arises in peripheral lung tissue, although location alone cannot establish the diagnosis. Invasive nonmucinous adenocarcinomas are described by architectural patterns, including lepidic, acinar, papillary, micropapillary, and solid growth. Lepidic growth means that tumor cells spread along pre-existing alveolar walls. Micropapillary and solid components generally indicate more aggressive behavior than predominantly lepidic growth, but interpretation also depends on invasion, tumor size, and other pathological features.\n\nAdenocarcinoma in situ and minimally invasive adenocarcinoma are narrowly defined lesions, not interchangeable labels for any small adenocarcinoma. Both measure no more than 3 cm and have predominantly lepidic growth; minimally invasive adenocarcinoma has an invasive component no larger than 5 mm. Additional exclusion criteria apply. These diagnoses ordinarily require examination of a completely resected lesion because a small sample cannot reliably exclude invasion elsewhere. They are associated with exceptionally favorable outcomes after complete resection.\n\nSquamous cell carcinoma shows keratinization, intercellular bridges, or supportive immunohistochemistry. It is strongly associated with tobacco exposure and often involves central airways, sometimes producing obstruction or cavitation. In poorly differentiated tumors, immunostains help establish lineage: thyroid transcription factor 1 and Napsin A support adenocarcinoma in an appropriate context, while p40 supports squamous differentiation. No stain is interpreted independently of morphology and clinical findings. Large-cell carcinoma is a diagnosis of exclusion made on adequately sampled resection material when recognizable glandular, squamous, and neuroendocrine differentiation are absent.\n\nModern histopathology aims to classify tumors while preserving material for predictive testing. The designation “NSCLC, not otherwise specified” remains useful when limited material cannot support a more precise classification, but its use has declined as immunohistochemical methods have improved. Distinguishing subtypes has direct treatment consequences: pemetrexed is used principally in nonsquamous disease, and bevacizumab is generally avoided in squamous lung cancer because of pulmonary bleeding risk."
    },
    {
      "heading": "Epidemiology, causes, prevention, and screening",
      "text": "Lung cancer caused approximately 2.5 million new cases and 1.8 million deaths worldwide in 2022, according to International Agency for Research on Cancer estimates. These figures include all histological types rather than NSCLC alone. Because NSCLC accounts for most lung cancers, it constitutes the largest share of that burden. Its epidemiology varies substantially with historical smoking patterns, occupational exposures, population age, and access to diagnosis. Adenocarcinoma is now the most common histological subtype in many populations.\n\nTobacco smoke contains carcinogens that damage DNA, including polycyclic aromatic hydrocarbons and tobacco-specific nitrosamines. Risk increases with cumulative exposure, although duration, intensity, age at initiation, and time since cessation all matter. Smoking cessation reduces subsequent risk, but risk can remain elevated for decades compared with that of people who never smoked. Secondhand tobacco smoke also causes lung cancer. The association is particularly strong for squamous and small-cell cancers, but smoking causes adenocarcinoma as well.\n\nImportant nontobacco causes include residential radon, outdoor air pollution, and occupational exposure to asbestos, crystalline silica, diesel exhaust, and certain metals. Radon is a radioactive gas whose decay products can irradiate airway cells after inhalation. Smoking and asbestos exposure together produce a particularly high lung-cancer risk. Chronic lung diseases, including some forms of pulmonary fibrosis, are also associated with increased risk. Familial aggregation reflects a mixture of shared exposures and inherited susceptibility; most NSCLC nevertheless arises without a recognizable hereditary cancer syndrome.\n\nLung cancer in people who have never smoked is a substantial clinical category, usually dominated by adenocarcinoma. Its frequency varies across populations, and actionable molecular alterations are more common in some never-smoking groups. However, smoking history does not reliably predict an individual tumor’s molecular profile. Demographic patterns therefore cannot substitute for tissue classification or molecular testing. Nor does the absence of an identified exposure establish that a tumor has a hereditary cause.\n\nPopulation prevention includes tobacco-control policies, reduced occupational exposure, radon mitigation, and improved air quality. Cancer screening with low-dose computed tomography can reduce lung-cancer mortality in selected high-risk populations. The US National Lung Screening Trial reported a 20% relative reduction in lung-cancer mortality compared with chest radiography in its initial analysis; the European NELSON trial also demonstrated a mortality benefit. Eligibility criteria vary by jurisdiction. Screening can detect curable tumors but also causes false-positive findings, incidental discoveries, radiation exposure, and overdiagnosis. It is distinct from diagnostic imaging performed because symptoms or an abnormal examination suggest existing disease."
    },
    {
      "heading": "Molecular biology and mechanisms of progression",
      "text": "NSCLC develops through accumulated genetic and epigenetic changes that alter cell proliferation, survival, differentiation, and interactions with surrounding tissue. Carcinogens can induce permanent changes in DNA, while errors arising during normal cell division also contribute. Tumor-suppressor genes such as TP53 and CDKN2A are frequently disrupted. These changes can weaken DNA-damage responses and cell-cycle control, allowing abnormal clones to expand. A tumor usually contains multiple related subclones rather than one genetically uniform population.\n\nSome tumors depend strongly on an oncogenic driver. Activating alterations in the epidermal growth factor receptor gene, EGFR, can produce persistent signaling through pathways controlling growth and survival. Recurrent exon 19 deletions and the exon 21 L858R substitution are common examples. Rearrangements involving ALK, ROS1, RET, or NTRK genes create abnormal fusion proteins. Other clinically important alterations include BRAF V600E, MET exon 14 skipping, KRAS G12C, and activating ERBB2, also called HER2, mutations. These alterations are especially relevant in adenocarcinoma, although no simple demographic rule identifies all affected tumors.\n\nDifferent driver alterations create different therapeutic dependencies. A kinase inhibitor may interrupt the signaling on which a tumor relies, producing substantial regression even in metastatic disease. This principle underlies targeted cancer therapy. However, driver-positive tumors are not biologically identical, and alterations within the same gene can respond differently. Common sensitizing EGFR mutations, EGFR exon 20 insertions, and acquired EGFR resistance mutations are distinct categories rather than interchangeable findings.\n\nTumor progression also involves invasion, angiogenesis, and metastasis. Cancer cells can cross tissue boundaries, enter blood or lymphatic vessels, and establish deposits in distant organs. The brain, bone, liver, adrenal glands, and opposite lung are frequent metastatic sites. Successful spread depends on both tumor-cell properties and the local environment at the destination. Within the primary tumor, fibroblasts, blood vessels, extracellular matrix, and immune cells influence growth and drug delivery.\n\nInteractions with the immune system provide another therapeutic target. Tumor expression of programmed death ligand 1, or PD-L1, can suppress antitumor T-cell activity through the PD-1 receptor. Blocking this pathway can restore immune activity in some patients. PD-L1 expression is an imperfect predictive marker, however, because responses also depend on antigen presentation, immune-cell infiltration, oncogenic signaling, and other factors. Treatment itself creates selective pressure: resistant subclones can expand, alternative signaling pathways can emerge, and some tumors undergo histological transformation. These processes explain why an initially effective therapy may later fail."
    },
    {
      "heading": "Clinical presentation and patterns of spread",
      "text": "Early NSCLC may produce no symptoms and may first appear as a pulmonary nodule on screening or imaging performed for another reason. Symptoms become more likely when a tumor obstructs an airway, invades adjacent structures, spreads to lymph nodes, or metastasizes. Persistent or changing cough, coughing up blood, shortness of breath, chest discomfort, recurrent infection, fatigue, and unintended weight loss are common presentations. None is specific to cancer, and their significance depends on the clinical context.\n\nCentral tumors can narrow a bronchus and cause collapse of downstream lung tissue or post-obstructive pneumonia. Infection may recur in the same region because the underlying obstruction persists. Peripheral tumors can involve the pleura and produce pleuritic pain or a pleural effusion. An effusion may result from malignant pleural involvement, impaired lymphatic drainage, infection, or another condition; imaging alone does not establish its cause.\n\nLocal invasion can produce anatomically distinctive syndromes. Involvement of the recurrent laryngeal nerve may cause hoarseness. A superior sulcus, or Pancoast, tumor at the lung apex can invade the lower brachial plexus, producing shoulder and arm pain, and may disrupt sympathetic nerves, causing Horner syndrome. Compression or invasion of the superior vena cava can impair venous drainage from the head, neck, and upper limbs. These manifestations reflect tumor location rather than a particular NSCLC histological subtype.\n\nDistant disease may dominate the initial presentation. Brain metastases can cause headache, seizures, focal weakness, or cognitive changes. Bone metastases may cause localized pain, fracture, or spinal instability; vertebral involvement can compress the spinal cord. Liver metastases may be asymptomatic initially or cause discomfort and abnormal liver tests. Adrenal metastases are common on imaging, but adrenal nodules are also frequently benign, so an isolated adrenal abnormality may require further characterization when it would change treatment intent.\n\nSystemic effects include appetite loss, reduced muscle mass, fatigue, and cancer-associated thrombosis. Paraneoplastic syndromes arise from substances produced by the tumor or from immune reactions rather than direct invasion. Squamous cell carcinoma can produce parathyroid hormone-related peptide, causing hypercalcemia. Hypertrophic pulmonary osteoarthropathy can produce clubbing and painful periosteal changes. Although some paraneoplastic syndromes are more characteristic of small-cell cancer, they are not confined to it. Clinical assessment also documents coexisting lung and cardiovascular disease, because these conditions affect both symptom interpretation and tolerance of treatment."
    },
    {
      "heading": "Diagnostic confirmation and predictive testing",
      "text": "Evaluation seeks to answer three separate questions: whether a lesion is malignant, what type of malignancy it represents, and how far it has spread. Chest computed tomography provides detailed information about the primary lesion, additional nodules, lymph nodes, and adjacent structures. Imaging appearances can suggest malignancy but generally cannot establish the histological diagnosis. Infection, inflammatory lesions, benign nodules, and metastases from cancers outside the lung remain part of the differential diagnosis.\n\nA biopsy or cytological specimen usually provides confirmation. The sampling method depends on lesion location and the information required. Bronchoscopy allows inspection and sampling of central airways. Endobronchial ultrasound-guided needle aspiration can sample mediastinal and hilar lymph nodes. Peripheral lesions may be sampled through image-guided transthoracic biopsy, navigational bronchoscopic techniques, or surgical excision. Pleural fluid cytology or biopsy of an accessible distant lesion can sometimes establish both diagnosis and advanced stage in one procedure.\n\nSpecimen handling is important because small samples must support several analyses. Pathologists establish morphology, use selected immunostains, and assess whether adequate tumor remains for molecular testing. Excessive use of stains can exhaust a specimen before predictive tests are completed. Necrosis, low tumor content, and some bone-decalcification methods can interfere with nucleic-acid analysis. A negative or nondiagnostic sample does not necessarily exclude malignancy if the sampled tissue was unrepresentative.\n\nMolecular profiling identifies alterations that can guide drug selection, particularly in advanced nonsquamous NSCLC and selected squamous tumors. Multigene panels using DNA sequencing, often supplemented by RNA analysis for fusions and splice alterations, can examine multiple targets simultaneously. PD-L1 immunohistochemistry addresses a different question: it measures protein expression associated with the probability of benefit from certain immunotherapy strategies. Assays, scoring systems, and treatment-specific thresholds are not universally interchangeable. A biomarker can be diagnostically informative without being predictive of response to a particular drug.\n\nPlasma testing for circulating tumor DNA provides a complementary form of liquid biopsy. A detected actionable alteration may provide useful treatment information when tissue is limited. However, some tumors shed little detectable DNA, particularly when disease volume is low or largely confined to the central nervous system. A negative plasma result therefore does not exclude a targetable alteration. Blood-derived clonal changes can also complicate interpretation. Tissue retains information about tumor architecture and transformation that plasma testing cannot fully replace, especially when disease behavior changes during treatment."
    },
    {
      "heading": "Anatomical staging and assessment of treatment fitness",
      "text": "Cancer staging describes anatomical extent and provides a common framework for treatment planning and comparison of outcomes. NSCLC uses the tumor–node–metastasis, or TNM, system. The T category incorporates primary-tumor size and specified features of local invasion or additional pulmonary nodules. The N category describes regional lymph-node involvement. The M category describes distant spread, including particular patterns of contralateral lung, pleural, pericardial, and extrathoracic disease. TNM editions change over time, so the edition matters when interpreting stage groups or comparing studies.\n\nClinical stage is assigned from the information available before definitive treatment. Pathological stage incorporates examination of resected tissue and lymph nodes. The two can differ because small nodal deposits or additional invasion may be invisible on imaging. Staging after preoperative treatment uses additional prefixes to indicate that therapy has altered the tumor. These distinctions prevent direct equivalence between, for example, an untreated clinical stage and the residual pathological stage after chemotherapy and immunotherapy.\n\nPositron emission tomography combined with CT, commonly using fluorodeoxyglucose, helps identify metabolically active nodal and distant disease. Uptake is not specific to cancer: inflammation, infection, and granulomatous disease can also be active. Conversely, small lesions and some less metabolically active tumors may show limited uptake. Suspicious findings often require tissue confirmation when they would change a potentially curative treatment plan. PET-CT also has limited sensitivity for brain metastases because normal brain tissue has high glucose uptake.\n\nContrast-enhanced magnetic resonance imaging is particularly useful for detecting brain metastases. The extent of brain imaging and invasive nodal staging depends on disease stage, symptoms, and the planned treatment. Endobronchial or esophageal ultrasound-guided sampling can establish mediastinal nodal involvement, while surgical mediastinal staging remains useful in selected circumstances. Distinguishing a separate primary lung cancer from an intrapulmonary metastasis may require integrated radiological, pathological, and molecular assessment rather than reliance on location alone.\n\nAnatomical resectability and physiological operability are different concepts. A tumor may be technically removable while the patient has insufficient cardiopulmonary reserve for the operation. Assessment therefore includes functional status, lung function, cardiovascular conditions, and the expected effect of removing lung tissue. Predicted postoperative forced expiratory volume and diffusing capacity are commonly considered; exercise testing adds information in selected cases. Frailty, nutritional state, kidney function, hearing, and coexisting autoimmune conditions may also affect the feasibility of particular systemic treatments. Multidisciplinary review brings these assessments together without reducing treatment selection to stage alone."
    },
    {
      "heading": "Treatment of localized and resectable disease",
      "text": "For localized NSCLC, treatment can have curative intent. Surgery removes the tumor and permits pathological assessment of margins and regional lymph nodes. Lobectomy has long been a standard operation for operable early disease, but the appropriate extent depends on tumor size, location, invasiveness, lung reserve, and nodal findings. Systematic lymph-node evaluation is important because occult nodal involvement changes prognosis and may alter postoperative treatment.\n\nRandomized evidence has refined the role of less extensive resection. The Japanese JCOG0802/WJOG4607L trial, reported in 2022, and the North American CALGB/Alliance 140503 trial, reported in 2023, supported sublobar resection in carefully selected patients with small peripheral, node-negative tumors. Their eligibility criteria, procedures, and endpoints differed. The results do not establish that a wedge resection is equivalent to lobectomy for every small lung cancer. Segmentectomy removes an anatomical bronchopulmonary segment, whereas wedge resection removes a nonanatomical portion; adequate margins and nodal assessment remain important.\n\nFor selected localized tumors in people who cannot undergo surgery, stereotactic body radiation therapy delivers highly focused radiation in a small number of treatments. It provides high local-control rates in medically inoperable early-stage NSCLC. Tumors near major central airways, the esophagus, or other critical structures require particular attention to dose and fractionation because severe injury can occur. Direct comparisons with surgery are difficult to interpret when the groups differ substantially in baseline health.\n\nTreatment around surgery addresses microscopic disease that may remain outside the resection field. Cisplatin-based adjuvant chemotherapy improves survival in appropriate resected stage groups, especially stage II and III disease, while benefit in stage I is more selective. Preoperative treatment can shrink tumors and address systemic disease early; postoperative treatment uses the pathological findings to refine selection. Trials distinguish overall survival from disease-free or event-free survival, and improvement in one endpoint does not automatically establish an identical effect on another.\n\nMolecularly selected and immune-based treatments have expanded perioperative therapy. In the ADAURA trial, adjuvant osimertinib improved disease-free survival and subsequently demonstrated an overall-survival benefit in resected NSCLC with common sensitizing EGFR mutations. The ALINA trial established a substantial disease-free-survival benefit for adjuvant alectinib in resected ALK-positive disease. Neoadjuvant and perioperative checkpoint-inhibitor regimens have also improved outcomes in defined resectable populations. Eligibility differs by stage, tumor characteristics, molecular findings, and jurisdiction. These approaches do not eliminate the importance of complete resection, treatment toxicity, or the possibility that a patient may not reach surgery after preoperative therapy."
    },
    {
      "heading": "Locally advanced and unresectable disease",
      "text": "Stage III NSCLC comprises heterogeneous patterns of locally advanced disease rather than one uniform treatment category. Some tumors are potentially resectable within a multimodality strategy, while others involve structures or nodal distributions that make definitive nonsurgical treatment more appropriate. Nodal bulk, the number and location of involved nodal stations, the feasibility of complete resection, and physiological fitness all influence this distinction. A stage label alone does not establish whether surgery is technically feasible or clinically appropriate.\n\nFor fit patients with unresectable stage III disease, concurrent platinum-based chemotherapy and thoracic radiation is an established treatment with curative intent. Chemotherapy treats microscopic systemic disease and can enhance radiation effects, while radiation provides locoregional control. Concurrent treatment generally achieves better outcomes than sequential treatment in appropriately selected populations but produces more acute toxicity, particularly esophagitis. Sequential treatment remains a separate strategy when concurrent treatment cannot be tolerated.\n\nRadiation planning must balance tumor coverage against exposure of the normal lung, heart, esophagus, spinal cord, and other structures. Modern techniques include intensity-modulated radiation therapy and image guidance. Radiation pneumonitis can develop after treatment, and later fibrosis can reduce pulmonary function. Dose escalation is not automatically beneficial: the RTOG 0617 trial found worse survival with 74 Gy than with the standard 60 Gy approach studied in its concurrent chemoradiation setting, demonstrating that a higher prescribed dose can worsen the overall therapeutic balance.\n\nThe PACIFIC trial changed treatment after definitive chemoradiation. In patients with unresectable stage III NSCLC whose disease had not progressed after concurrent chemoradiation, consolidation durvalumab improved progression-free and overall survival compared with placebo. Five-year overall survival was approximately 43% with durvalumab and 33% with placebo. Trial eligibility, recovery from chemoradiation, pneumonitis risk, and regional regulatory requirements affect applicability. Radiation injury and immune-mediated pneumonitis can overlap clinically and radiologically, complicating diagnosis.\n\nMolecularly defined disease has introduced additional distinctions. In the LAURA trial, reported in 2024, osimertinib after definitive chemoradiation markedly prolonged progression-free survival in unresectable stage III NSCLC with specified sensitizing EGFR mutations; overall-survival data were immature in the initial report. This setting illustrates why evidence from a broad NSCLC population cannot automatically be transferred to every molecular subgroup. Some selected patients with limited metastatic disease also receive intensive treatment to all visible sites, but this is distinct from conventional stage III management and depends on the distribution, biology, and response of the disease."
    },
    {
      "heading": "Systemic treatment of metastatic disease",
      "text": "Metastatic NSCLC is generally treated with systemic therapy intended to prolong survival, control disease, and reduce symptoms. Treatment is organized around histology, actionable molecular alterations, PD-L1 expression, prior treatment, disease distribution, and functional status. These factors are interdependent. For example, high PD-L1 expression does not remove the relevance of an EGFR mutation or ALK rearrangement. Tumor biology can therefore determine the first major treatment branch before conventional distinctions between chemotherapy regimens are considered.\n\nTargeted drugs can produce substantial and sometimes prolonged responses in tumors with matching alterations. Osimertinib is active against common sensitizing EGFR mutations and has important central nervous system activity. Alectinib, brigatinib, and lorlatinib are examples of ALK inhibitors used in appropriate settings. Other drug classes target ROS1, RET, MET exon 14 skipping, BRAF V600E, NTRK fusions, and particular KRAS or HER2 alterations. Availability and approved treatment lines vary. An alteration in a named gene is not sufficient by itself: the specific variant must match the biological and clinical evidence for the drug.\n\nFor tumors without an actionable driver, immune checkpoint inhibitors are central to many first-line regimens. These drugs block PD-1, PD-L1, or CTLA-4 signaling and can generate durable disease control in a subset of patients. Depending on PD-L1 level and other eligibility factors, they may be used alone or with chemotherapy. KEYNOTE-024 established pembrolizumab monotherapy in a selected high-PD-L1 population without sensitizing EGFR or ALK alterations. KEYNOTE-189 and KEYNOTE-407 demonstrated survival benefits from adding pembrolizumab to chemotherapy in metastatic nonsquamous and squamous NSCLC, respectively.\n\nHistology influences the chemotherapy backbone. Platinum plus pemetrexed is widely used in nonsquamous disease, whereas platinum plus a taxane is a common component in squamous disease. Maintenance treatment can continue selected drugs after an initial combination phase. Subsequent treatment depends on what has already been given and why it stopped. Acquired resistance may prompt repeat tissue or plasma testing to identify a new target, while isolated progression in one or a few sites can sometimes be addressed locally without immediately abandoning an otherwise effective systemic treatment.\n\nBenefits must be considered alongside distinct toxicities. Platinum drugs can cause marrow suppression, nausea, kidney injury, or neuropathy, with differences between agents. Targeted drugs can cause rash, diarrhea, liver abnormalities, cardiac effects, or interstitial lung disease, depending on the agent. Cancer immunotherapy can cause immune-mediated inflammation affecting the lungs, bowel, liver, endocrine organs, skin, and other tissues. Antibody–drug conjugates add another therapeutic mechanism by delivering a cytotoxic payload to cells bearing a selected target, but their adverse effects and biomarker requirements differ from those of conventional kinase inhibitors."
    },
    {
      "heading": "Prognosis, supportive care, and research questions",
      "text": "Prognosis varies widely across NSCLC. Stage at diagnosis is a major determinant, but outcomes also depend on histological features, molecular subtype, treatment response, functional status, and coexisting illness. Population registries show markedly better survival for localized disease than for distant disease. Such statistics describe groups diagnosed in particular periods; they can lag behind treatment advances and do not determine an individual outcome. Five-year relative survival also differs conceptually from overall survival reported in a trial, because it adjusts for expected mortality in a comparable general population.\n\nRecurrence can occur locally, in regional nodes, or at distant sites after apparently curative treatment. Surveillance commonly relies on scheduled clinical assessment and chest CT, with additional investigations directed by findings. A new lung lesion may represent recurrence, a second primary cancer, infection, or a benign process. Distinguishing these possibilities can change treatment intent. Long-term survivors may also experience reduced exercise tolerance, postoperative pain, neuropathy, radiation-related changes, or persistent endocrine dysfunction after immunotherapy.\n\nPalliative care addresses symptoms, communication, psychosocial concerns, and the burdens of serious illness alongside cancer-directed treatment. It is not restricted to the final phase of life. A randomized study reported by Jennifer Temel and colleagues in 2010 found that early integrated palliative care for metastatic NSCLC improved quality of life and mood; longer survival was also observed in that trial. Supportive care encompasses management of pain, breathlessness, pleural effusions, nausea, fatigue, nutritional problems, and treatment complications. Rehabilitation and attention to health-related quality of life address functional outcomes not captured by tumor measurements alone.\n\nResearch endpoints require careful interpretation. Overall survival directly measures death from any cause, while progression-free survival measures the interval until progression or death under a specified assessment system. Pathological complete response, major pathological response, and molecular clearance may provide earlier signals, but their value as a surrogate endpoint depends on the treatment and disease setting. A high response rate does not by itself establish longer survival or better quality of life. Crossover, later therapies, follow-up duration, and trial eligibility also affect interpretation of a randomized controlled trial.\n\nActive research concerns include resistance mechanisms, optimal treatment sequencing, central nervous system disease, and the use of circulating tumor DNA to identify molecular residual disease after curative-intent treatment. Detecting residual DNA can indicate a higher recurrence risk, but a prognostic association does not by itself prove that changing treatment on that basis improves outcomes. Additional work addresses underrepresented populations, older adults, and people with substantial comorbidity, who may differ from trial participants. Access to timely diagnosis, comprehensive biomarker testing, specialist care, and effective drugs remains an important source of variation between health systems and patient populations."
    }
  ],
  "links": [
    "lung-cancer",
    "carcinoma",
    "histopathology",
    "epidemiology",
    "cancer-screening",
    "overdiagnosis",
    "dna",
    "targeted-cancer-therapy",
    "metastasis",
    "immune-system",
    "cough",
    "shortness-of-breath",
    "pneumonia",
    "x-ray-computed-tomography",
    "differential-diagnosis",
    "biopsy",
    "dna-sequencing",
    "biomarker",
    "liquid-biopsy",
    "cancer-staging",
    "positron-emission-tomography",
    "magnetic-resonance-imaging",
    "surgery",
    "radiation-therapy",
    "chemotherapy",
    "intensity-modulated-radiation-therapy",
    "immune-checkpoint-inhibitor",
    "cancer-immunotherapy",
    "antibody-drug-conjugate",
    "prognosis",
    "palliative-care",
    "rehabilitation",
    "health-related-quality-of-life",
    "surrogate-endpoint",
    "randomized-controlled-trial"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}